NCT04926831 2025-10-16
Geometry-N
Novartis
Phase 2 Terminated
Clinical Trials
7 trialsNCT04427072 2025-05-16
GeoMETry-III
Novartis
Phase 3 Terminated
NCT04139317 2024-10-09
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
Novartis
Phase 2 Terminated
NCT04323436 2024-10-09
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
Novartis
Phase 2 Terminated
NCT05435846 2024-06-11
Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
University of California, San Francisco
Phase 1 Terminated
NCT02335944 2023-06-18
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
Novartis
Phase 1/2 Terminated
NCT02323126 2022-02-28
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
Novartis
Phase 2 Terminated